Ascendis Pharma A/S's (ASND) Outperform Rating Reiterated at Oppenheimer

Oppenheimer reaffirmed their outperform rating on shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in a research report sent to investors on Tuesday morning, Benzinga reports. They currently have a $190.00 price objective on the biotechnology company's stock, up from their prior price objective of $180.00.

Several other research firms also recently weighed in on ASND. TD Cowen dropped their target price on shares of Ascendis Pharma A/S from $175.00 to $157.00 and set a buy rating on the stock in a research report on Wednesday, September 4th. The Goldman Sachs Group lifted their price objective on shares of Ascendis Pharma A/S from $170.00 to $195.00 and gave the stock a buy rating in a research report on Tuesday, August 13th. Cantor Fitzgerald restated an overweight rating and issued a $170.00 target price on shares of Ascendis Pharma A/S in a report on Monday. Citigroup lowered their price target on Ascendis Pharma A/S from $193.00 to $178.00 and set a buy rating on the stock in a report on Wednesday, September 4th. Finally, Stifel Nicolaus initiated coverage on Ascendis Pharma A/S in a research report on Friday, May 31st. They set a buy rating and a $200.00 price target on the stock. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, Ascendis Pharma A/S currently has a consensus rating of Moderate Buy and an average target price of $193.77.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ:ASND traded up $7.02 during midday trading on Tuesday, reaching $146.59. The company had a trading volume of 1,993,209 shares, compared to its average volume of 435,695. The company has a fifty day simple moving average of $132.51 and a two-hundred day simple moving average of $136.47. The firm has a market cap of $8.54 billion, a price-to-earnings ratio of -14.97 and a beta of 0.63. Ascendis Pharma A/S has a 1-year low of $85.29 and a 1-year high of $161.00.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vestal Point Capital LP bought a new stake in Ascendis Pharma A/S in the fourth quarter worth approximately $78,719,000. GSA Capital Partners LLP acquired a new position in Ascendis Pharma A/S during the first quarter worth $992,000. Price T Rowe Associates Inc. MD raised its holdings in Ascendis Pharma A/S by 23.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company's stock valued at $269,374,000 after buying an additional 336,976 shares in the last quarter. ADAR1 Capital Management LLC bought a new position in Ascendis Pharma A/S during the fourth quarter valued at about $5,779,000. Finally, Perceptive Advisors LLC acquired a new stake in shares of Ascendis Pharma A/S in the fourth quarter worth about $16,648,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.